Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Rosiglitazone

Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.

Trial Locations (4)

CB2 2GG

Addenbrooke's Hospital, Cambridge

UB1 3HW

Ealing Hospital, London

W12 ONN

Imperial College London - Hammersmith Campus, London

W6 8RF

Charing Cross Hospital, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Imperial College London

OTHER